Lichen planus (LP), a relatively common mucocutaneous disease. Activated T cells are important in the pathogenesis of LP as indicated by the dermal lymphocytic infiltrate leading to keratinocyte destruction and lesion formation. Mycophenolate mofetil (MMF), which specifically and reversibly inhibits the proliferation of activated T cells, was introduced in the treatment of autoimmune and inflammatory skin disorders. Furthermore, MMF has also been successfully used in the treatment of graft-versus-host disease (GVHD). Both GVHD and LP are characterized by activated T cells, which play a pivotal role in lesion formation. Thus, we have used MMF for the treatment of oral lichen planus (OLP). In this double blind trial, 27 patients, referring to Oral Medicine Department of Tabriz Dental School were recruited.10 patients have bilateral ulcerative lesions of OLP and they will be enrolled in a double blind clinical trial study (group A). 17 patients which have unilateral ulcerative lesion of OLP, will be enrolled in a before-after clinical trial study (group B).The lesion size with digital culis and pain quantity with Visual Analogue Scaling (VAS) will be recorded before and after treatment. In group A, patients will be instructed to put 2% MMF mucoadhesive on one of the dried lesions and put the placebo on the other one, twice daily for 4 weeks. In group B, patients will use only 2% MMF mucoadhesive in the same manner. Results will be analyzed by McNemar's test and wilcoxon test by using of spss software.